Loxtidine
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| [1-methyl-5-({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino)-1H-1,2,4-triazol-3-yl]methanol | |
| Clinical data | |
| Legal status | Uncontrolled |
| Routes | Oral |
| Identifiers | |
| CAS number | 76956-02-0 |
| ATC code | None |
| PubChem | CID 55473 |
| ChemSpider | 50093 |
| UNII | X16K5179V5 |
| Chemical data | |
| Formula | C19H29N5O2 |
| Mol. mass | 359.47 g/mol |
| SMILES
| |
Lavoltidine (INN, USAN, BAN; code name AH-23,844), previously known as loxtidine, is a highly potent and selective H2 receptor antagonist which was under development as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[1][2]
Adverse effects
Antacid preparations such as loxtidine by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food or drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.[3]
See also
References
- ↑ Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
- ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
- ↑ Pali-Schöll I, Jensen-Jarolim E (April 2011). "Anti-acid medication as a risk factor for food allergy". Allergy 66 (4): 469–77. doi:10.1111/j.1398-9995.2010.02511.x. PMID 21121928.
| ||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.